Novel biomarkers for the detection of prostate cancer

Journal article

Abstract:: Prostate-specific antigen (PSA) is widely used as a biomarker in the detection of prostate cancer and for decision making regarding treatment options, response to therapy, and clinical follow-up. Despite its widespread use, it is well recognised that PSA has suboptimal performance as a screening tool due to poor specificity, resulting in high negative biopsy rates and potential 'over-diagnosis' and 'over-treatment' of clinically insignificant cancers. In particular, PSA does not reliably distinguish either cancer from benign prostatic conditions, or 'clinically significant' from 'indolent cancers', and it is inaccurate in predicting disease burden and response to treatment. There is an urgent demand for novel biomarkers to address these clinical needs. This article provides an update on the novel candidate biomarkers in development, which have shown potential for improving the detection of clinically significant cases of this malignancy.

Files:: 2051415816656121.pdf

(Preview, Version of record, pdf, 894.3KB, Terms of use)

Language:: English
Keywords:: prostate cancer

detection

diagnosis

biomarker

kallikrein panel

screening

PSA
Pubs id:: pubs:687294
UUID:: uuid:19a41c11-f627-446f-b147-c0f5054680fe
Local pid:: pubs:687294
Source identifiers:: 687294
Deposit date:: 2017-08-08

Copyright holder:: British Association of Urological Surgeons
Notes:: Copyright © 2017 British Association of Urological Surgeons. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

If you are the owner of this record, you can report an update to it here: Report update to this record